{"product_id":"pfe-bcg-matrix","title":"(PFE) Pfizer Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Pfizer Inc. BCG Matrix is a ready-made strategic analysis that helps you see how the company’s products or business units may fit into the Stars, Cash Cows, Question Marks, and Dogs framework. The page already shows a real preview of the actual report content, so you can review what you’re getting before buying. Purchase the full version to access the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVyndaqel family 5B+ ATTR growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePfizer’s Vyndaqel\/Vyndamax franchise posted about $5.0 billion in 2024 revenue, making it one of the company’s biggest growth engines. ATTR cardiomyopathy diagnosis and treatment rates kept rising into 2025 as awareness and screening expanded. With a leading share in a still-growing rare-disease market, the franchise fits the Star quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePadcev 1B+ urothelial cancer growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePadcev gained scale after the EV-302 combo with pembrolizumab became a first-line standard for locally advanced or metastatic urothelial cancer, with median overall survival of 31.5 vs 16.1 months and median PFS of 12.5 vs 6.3 months. Astellas reported FY2024 Padcev sales of ¥189.4 billion, showing 1B-plus market scale. That makes it a Star candidate for Pfizer: fast growth, stronger penetration, and a wider bladder-cancer market through 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrevnar 20 6B pneumococcal franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrevnar 20 anchors Pfizer Inc.’s pneumococcal franchise, which is about $6B in scale. In 2025, adult and pediatric PCV20 use kept the business large, and the 20-valent design gave broad serotype coverage. High share in a broad vaccine market supports Star status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNurtec ODT 1B migraine brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNurtec ODT is a $1B-plus migraine brand for Pfizer Inc., and it is used for both acute treatment and prevention. The CGRP class keeps taking share from older migraine drugs, so Pfizer has a strong position in a still-expanding market. That mix of scale, dual use, and category growth fits a Star in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1B-plus brand\u003c\/li\u003e\n\u003cli\u003eAcute and preventive use\u003c\/li\u003e\n\u003cli\u003eCGRP share gain\u003c\/li\u003e\n\u003cli\u003eStar profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAbrysvo RSV launch brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbrysvo has two approved RSV paths: adults 60+ and maternal vaccination, which gives Pfizer Inc. a broader launch base than a single-use brand. RSV vaccination is still in an adoption phase, so the category is early and growth can stay steep if uptake keeps building. The maternal niche is especially important because it opens a second, high-value demand pool and supports a Star label in the BCG matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo indications widen launch reach\u003c\/li\u003e\n\u003cli\u003eEarly market means room to grow\u003c\/li\u003e\n\u003cli\u003eMaternal use is the key growth engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer’s 2025 Star Brands: Scale, Growth, and Expanding Use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePfizer Inc.’s Stars are the franchises with strong 2025 scale and clear growth: Vyndaqel\/Vyndamax near $5.0B in 2024 sales, Prevnar 20 around $6B, and Nurtec ODT above $1B. Padcev and Abrysvo also fit, backed by 2025 market expansion and broader use in bladder cancer and RSV.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025 Star signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVyndaqel\/Vyndamax\u003c\/td\u003e\n\u003ctd\u003e$5.0B 2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevnar 20\u003c\/td\u003e\n\u003ctd\u003e~$6B scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNurtec ODT\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$1B and growing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePadcev\u003c\/td\u003e\n\u003ctd\u003e1L bladder cancer growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbrysvo\u003c\/td\u003e\n\u003ctd\u003e2 RSV indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003ePfizer’s BCG Matrix maps its drug portfolio to spot growth bets, cash cows, and potential divestments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Pfizer BCG Matrix to quickly spot stars, cash cows, and drag points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLists credible sources behind Pfizer Inc. claims to boost trust, speed due diligence, and support sharper decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComirnaty 5B+ mature COVID vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eComirnaty stayed a key cash cow for Pfizer Inc., with 2024 sales of about $5.3 billion, even as COVID demand cooled from pandemic peaks. The market is now booster-led and seasonal, not hypergrowth-driven, so cash flow is steadier but slower.\u003c\/p\u003e\n\u003cp\u003eThat makes Comirnaty fit the BCG Cash Cow box: high share in a mature market, low growth, and strong monetization of Pfizer’s global vaccine reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremarin family long-running women health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePremarin has been in women’s health for decades, and its demand is steady because postmenopausal hormone therapy is a mature, low-growth category. High brand recognition and a long safety\/usage history support repeat prescriptions, which is why it fits the Cash Cow bucket in Pfizer Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBeneFIX hemophilia B legacy brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBeneFIX (nonacog alfa) is Pfizer Inc.'s long-running recombinant factor IX brand, used in a mature hemophilia B market that remains steady because treatment is lifelong. Hemophilia B makes up about 15% of hemophilia cases, or roughly 1 in 25,000 male births, so demand is small but durable. That profile supports steady cash flow with limited growth pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRetacrit mature ESA biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRetacrit is Pfizer Inc.'s mature epoetin alfa-epbx biosimilar in anemia and nephrology, where pricing is tight but hospital and dialysis demand stays steady. That makes it a classic Cash Cow: low growth, durable volume, and recurring use in chronic kidney disease care.\u003c\/p\u003e\n\u003cp\u003ePfizer still benefits from established formulary access and repeat treatment cycles, even as biosimilar competition keeps margins under pressure. The asset fits a harvest-and-defend role inside Pfizer Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable dialysis-channel volume\u003c\/li\u003e\n\u003cli\u003ePrice pressure, but sticky demand\u003c\/li\u003e\n\u003cli\u003eMature biosimilar cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEliquis recurring anticoagulant revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn late 2025, Eliquis still looks like a Cash Cow for Pfizer Inc. because it sits in a mature anticoagulant market with steady repeat prescribing, not a high-growth launch curve. Pfizer reported about $7.2 billion of Eliquis revenue in 2024, and that kind of scale points to durable, recurring cash flow rather than heavy reinvestment needs.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAbout $7.2B Pfizer revenue in 2024\u003c\/li\u003e\n\u003cli\u003eLarge, established anticoagulant market\u003c\/li\u003e\n\u003cli\u003eRepeat prescriptions support stable demand\u003c\/li\u003e\n\u003cli\u003eFits Cash Cow, not rapid-growth launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer’s cash cows keep delivering billions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePfizer Inc.'s cash cows remain mature, high-share brands with steady repeat use and limited growth. Eliquis brought about $7.2B in 2024 sales, while Comirnaty still added about $5.3B, showing durable cash flow even as demand normalized.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 sales\u003c\/th\u003e\n\u003cth\u003eBCG role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEliquis\u003c\/td\u003e\n\u003ctd\u003e$7.2B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eComirnaty\u003c\/td\u003e\n\u003ctd\u003e$5.3B\u003c\/td\u003e\n\u003ctd\u003eCash Cow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003ePfizer Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Pfizer Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No placeholders, no demo pages—just the full, ready-to-use report.\u003c\/p\u003e\n\u003cp\u003eOnce purchased, this final version is instantly available for download and review. It’s formatted for clear strategic analysis and professional use.\u003c\/p\u003e\n\u003cp\u003eWhat you preview is what you get, with no changes or surprises. Use it for planning, presentations, or competitive analysis with confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIbrance 3B and declining\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIbrance remains a Dog in Pfizer Inc.’s BCG Matrix. FY2024 sales fell to about $2.7B from $3.1B in FY2023 as Verzenio and Kisqali kept taking share in the CDK4\/6 breast-cancer class. The market is still large, but Ibrance’s shrinking revenue and weaker growth momentum show eroding position, not a star or cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXeljanz pressure from JAK rivals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXeljanz sits in a crowded JAK market, and the class still carries FDA boxed-warning safety scrutiny tied to higher risks seen in the 2021 ORAL Surveillance data. Pfizer’s Xeljanz sales were about $1.0 billion in 2024, down from its peak, showing weak growth and heavy rivalry from newer immunology drugs. That profile fits a Dog in the BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePaxlovid post-peak antiviral\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePaxlovid fits Pfizer Inc.’s Dogs bucket by end-2025: it peaked at about $18.9 billion in 2022, then COVID treatment demand fell hard as the emergency phase ended. Pfizer Inc. said Paxlovid sales stayed far below peak levels in 2024, showing a low-growth, low-share asset. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eXtandi mature prostate cancer therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eXtandi is a mature prostate cancer asset for Pfizer Inc., with limited room to expand as newer androgen-receptor options keep pressure on pricing and share. In 2025, the prostate cancer drug market stayed crowded, and Xtandi’s growth looked modest versus faster-growing oncology launches. That makes the asset fit a Dog profile in Pfizer Inc.’s BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature brand, low growth\u003c\/li\u003e\n\u003cli\u003eIntense prostate cancer rivalry\u003c\/li\u003e\n\u003cli\u003eWeak upside for Pfizer Inc.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInflectra commoditized biosimilar\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInflectra is a commoditized infliximab biosimilar in a crowded market with multiple rivals, so price cuts, not differentiation, drive demand. Pfizer's own biosimilar portfolio has faced thin margins here, and Inflectra’s growth is capped as more payers and hospitals switch to the lowest-cost option. That makes it a clear Dog in the BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh pricing pressure\u003c\/li\u003e\n\u003cli\u003eLimited growth runway\u003c\/li\u003e\n\u003cli\u003eLow-margin biosimilar\u003c\/li\u003e\n\u003cli\u003eDog classification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer’s Dog Drugs Keep Losing Ground\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePfizer Inc.’s Dog assets stay under pressure: Ibrance fell to about $2.7B in FY2024, Xeljanz to about $1.0B, Paxlovid was far below its $18.9B 2022 peak, and Inflectra faces low-price biosimilar rivalry. These drugs show weak growth, shrinking share, and limited upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDrug\u003c\/th\u003e\n\u003cth\u003eFY2024 sales\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIbrance\u003c\/td\u003e\n\u003ctd\u003e$2.7B\u003c\/td\u003e\n\u003ctd\u003eDeclining\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXeljanz\u003c\/td\u003e\n\u003ctd\u003e$1.0B\u003c\/td\u003e\n\u003ctd\u003eStalled\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHympavzi early hemophilia entrant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHympavzi is Pfizer Inc.’s early hemophilia prophylaxis entrant, so it sits in the Question Marks bucket: low share today, but with room to grow. Non-factor prevention is the faster-expanding part of hemophilia care, and Pfizer’s 2024 launch gives it a real shot to win share. It needs spending on access, data, and sales now to turn momentum into a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElrexfio early multiple myeloma launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElrexfio is still in the launch phase, so its sales base is small versus Pfizer Inc.’s larger oncology portfolio. Multiple myeloma is a growing market, but it is crowded with strong rivals like Johnson \u0026amp; Johnson and Bristol Myers Squibb, so share gains are slow. That puts Elrexfio in Question Marks: clear upside, but low current share and still limited traction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLitfulo small alopecia areata share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLitfulo is still a small brand in alopecia areata, a disease that affects about 2% of people worldwide. Pfizer launched Litfulo in 2023, so the franchise is still early in its buildout. It is growing in a dermatology market led by bigger, more established rivals, which fits a classic Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZavzpret crowded migraine market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZavzpret sits in a growing but crowded acute-migraine market, where CGRP drugs compete with triptans and newer rivals. Pfizer launched Zavzpret in 2023, so the brand is still early and sales scale is modest versus category leaders. Low share in an expanding market makes it a clear Question Mark in Pfizer Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing migraine category\u003c\/li\u003e\n\u003cli\u003eHeavy competition\u003c\/li\u003e\n\u003cli\u003eStill small brand\u003c\/li\u003e\n\u003cli\u003eQuestion Mark status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVelsipity ulcerative colitis launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVelsipity is a newer ulcerative colitis therapy, launched after U.S. FDA approval in 2023 for adults with moderately to severely active disease. In a large, growing IBD market, Pfizer Inc. still has a small share here, so the brand fits Question Mark status.\u003c\/p\u003e\n\u003cp\u003eIt needs faster uptake in gastroenterology, stronger formulary access, and more repeat prescribing before it can become a Star. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew launch, still early share\u003c\/li\u003e\n\u003cli\u003eIBD demand remains large and growing\u003c\/li\u003e\n\u003cli\u003eMore uptake is needed to scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer’s New Launches: Early Traction, Big Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePfizer Inc.’s Question Marks are newer, low-share launches in growing markets: Hympavzi, Elrexfio, Litfulo, Zavzpret, and Velsipity. They all need more spend, access wins, and repeat use to move up from early traction; until then, their upside is real but unproven.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025\/2026 view\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHympavzi\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e2024 launch, early hemophilia share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElrexfio\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003eSmall base in crowded myeloma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitfulo\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e2023 launch, early alopecia build\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZavzpret\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e2023 launch, modest migraine share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVelsipity\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e2023 FDA launch, still early IBD uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191844839689,"sku":"pfe-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pfe-bcg-matrix.webp?v=1783678587","url":"https:\/\/dcfanalyst.com\/products\/pfe-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}